Use of EL-FIT App to Promote Physical Activity
Conditions:   End Stage Liver DIsease;   Cirrhosis, Liver Intervention:   Behavioral: Fitness intervention Sponsors:   University of Pittsburgh;   American Association for the Study of Liver Diseases (AASLD);   Pittsburgh Liver Research Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2020 Category: Research Source Type: clinical trials

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
Conditions:   Primary Biliary Cholangitis;   Primary Biliary Cirrhosis;   Cholangitis;   Cholestasis;   Biliary Tract Diseases;   Bile Duct Stricture Intervention:   Drug: HTD1801 (BUDCA) Sponsor:   HighTide Biopharma Pty Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2020 Category: Research Source Type: clinical trials

Use of EL-FIT App to Promote Physical Activity
Conditions:   End Stage Liver DIsease;   Cirrhosis, Liver Intervention:   Behavioral: Fitness intervention Sponsors:   University of Pittsburgh;   American Association for the Study of Liver Diseases (AASLD);   Pittsburgh Liver Research Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2020 Category: Research Source Type: clinical trials

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
Conditions:   Primary Biliary Cholangitis;   Primary Biliary Cirrhosis;   Cholangitis;   Cholestasis;   Biliary Tract Diseases;   Bile Duct Stricture Intervention:   Drug: HTD1801 (BUDCA) Sponsor:   HighTide Biopharma Pty Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2020 Category: Research Source Type: clinical trials

Use of EL-FIT App to Promote Physical Activity
Conditions:   End Stage Liver DIsease;   Cirrhosis, Liver Intervention:   Behavioral: Fitness intervention Sponsors:   University of Pittsburgh;   American Association for the Study of Liver Diseases (AASLD);   Pittsburgh Liver Research Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2020 Category: Research Source Type: clinical trials

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
Conditions:   Primary Biliary Cholangitis;   Primary Biliary Cirrhosis;   Cholangitis;   Cholestasis;   Biliary Tract Diseases;   Bile Duct Stricture Intervention:   Drug: HTD1801 (BUDCA) Sponsor:   HighTide Biopharma Pty Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2020 Category: Research Source Type: clinical trials

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
AbstractObjectivesWe will evaluate the efficacy and safety of favipiravir and interferon beta-1a compared to lopinavir/ritonavir and interferon beta-1a in patients with confirmed COVID-19, who are moderately ill.Trial designThis is a phase 3, single-center, randomized, open-label, controlled trial with a parallel-group design carried out at Shahid Mohammadi Hospital, Bandar Abbas, Iran.ParticipantsAll patients with age  ≥ 20 years admitted at the Severe Acute Respiratory Syndrome Departments of the Shahid Mohammadi Hospital, Bandar Abbas, Iran, will be screened for the following criteria.Inclusion c...
Source: Trials - October 27, 2020 Category: Research Source Type: clinical trials

Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial
AbstractObjectivesWe will evaluate the efficacy and safety of Melatonin, compared to the standard therapeutic regimen on clinical symptoms and serum inflammatory parameters in patients with confirmed COVID-19, who are moderately ill.Trial designThis is a single-center, randomized, double-blind, placebo-controlled clinical trial with a parallel-group design conducted at Shahid Mohammadi Hospital, Bandar Abbas, Iran.ParticipantsAll patients admitted to Severe Acute Respiratory Syndrome Departments of Shahid Mohammadi Hospital, Bandar Abbas, Iran will be screened for the following criteria.Inclusion criteria:1. Age ≥20 yea...
Source: Trials - October 26, 2020 Category: Research Source Type: clinical trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis;   Fibrosis, Liver;   Type 1 Diabetes;   Cirrhosis, Liver Intervention:   Device: Transient Elastography Sponsor:   Joslin Diabetes Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis;   Fibrosis, Liver;   Type 1 Diabetes;   Cirrhosis, Liver Intervention:   Device: Transient Elastography Sponsor:   Joslin Diabetes Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis;   Fibrosis, Liver;   Type 1 Diabetes;   Cirrhosis, Liver Intervention:   Device: Transient Elastography Sponsor:   Joslin Diabetes Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis;   Fibrosis, Liver;   Type 1 Diabetes;   Cirrhosis, Liver Intervention:   Device: Transient Elastography Sponsor:   Joslin Diabetes Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis;   Fibrosis, Liver;   Type 1 Diabetes;   Cirrhosis, Liver Intervention:   Device: Transient Elastography Sponsor:   Joslin Diabetes Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis;   Fibrosis, Liver;   Type 1 Diabetes;   Cirrhosis, Liver Intervention:   Device: Transient Elastography Sponsor:   Joslin Diabetes Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis;   Fibrosis, Liver;   Type 1 Diabetes;   Cirrhosis, Liver Intervention:   Device: Transient Elastography Sponsor:   Joslin Diabetes Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis;   Fibrosis, Liver;   Type 1 Diabetes;   Cirrhosis, Liver Intervention:   Device: Transient Elastography Sponsor:   Joslin Diabetes Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis;   Fibrosis, Liver;   Type 1 Diabetes;   Cirrhosis, Liver Intervention:   Device: Transient Elastography Sponsor:   Joslin Diabetes Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis;   Fibrosis, Liver;   Type 1 Diabetes;   Cirrhosis, Liver Intervention:   Device: Transient Elastography Sponsor:   Joslin Diabetes Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials

Angiotensin 2 for AKI After OLT
Conditions:   Cirrhosis, Liver;   End Stage Liver DIsease;   Acute Kidney Injury;   Liver Transplant; Complications Interventions:   Drug: Angiotensin II;   Drug: Norepinephrine Sponsor:   University of California, Los Angeles Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Fecal Microbiota Transplantation in Cirrhosis
Condition:   Cirrhosis, Liver Intervention:   Other: Healthy fecal bacteria liquid Sponsor:   First Affiliated Hospital of Wenzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Angiotensin 2 for AKI After OLT
Conditions:   Cirrhosis, Liver;   End Stage Liver DIsease;   Acute Kidney Injury;   Liver Transplant; Complications Interventions:   Drug: Angiotensin II;   Drug: Norepinephrine Sponsor:   University of California, Los Angeles Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Fecal Microbiota Transplantation in Cirrhosis
Condition:   Cirrhosis, Liver Intervention:   Other: Healthy fecal bacteria liquid Sponsor:   First Affiliated Hospital of Wenzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Angiotensin 2 for AKI After OLT
Conditions:   Cirrhosis, Liver;   End Stage Liver DIsease;   Acute Kidney Injury;   Liver Transplant; Complications Interventions:   Drug: Angiotensin II;   Drug: Norepinephrine Sponsor:   University of California, Los Angeles Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Fecal Microbiota Transplantation in Cirrhosis
Condition:   Cirrhosis, Liver Intervention:   Other: Healthy fecal bacteria liquid Sponsor:   First Affiliated Hospital of Wenzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Conditions:   Hepatitis B;   Cirrhosis, Liver;   Chronic Liver Disease Interventions:   Biological: Heplisav-B Injectable Product, 2-dose regimen;   Biological: Heplisav-B Injectable Product, 3-dose regimen Sponsor:   Mercy Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Angiotensin 2 for AKI After OLT
Conditions:   Cirrhosis, Liver;   End Stage Liver DIsease;   Acute Kidney Injury;   Liver Transplant; Complications Interventions:   Drug: Angiotensin II;   Drug: Norepinephrine Sponsor:   University of California, Los Angeles Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Fecal Microbiota Transplantation in Cirrhosis
Condition:   Cirrhosis, Liver Intervention:   Other: Healthy fecal bacteria liquid Sponsor:   First Affiliated Hospital of Wenzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Conditions:   Hepatitis B;   Cirrhosis, Liver;   Chronic Liver Disease Interventions:   Biological: Heplisav-B Injectable Product, 2-dose regimen;   Biological: Heplisav-B Injectable Product, 3-dose regimen Sponsor:   Mercy Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Angiotensin 2 for AKI After OLT
Conditions:   Cirrhosis, Liver;   End Stage Liver DIsease;   Acute Kidney Injury;   Liver Transplant; Complications Interventions:   Drug: Angiotensin II;   Drug: Norepinephrine Sponsor:   University of California, Los Angeles Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Fecal Microbiota Transplantation in Cirrhosis
Condition:   Cirrhosis, Liver Intervention:   Other: Healthy fecal bacteria liquid Sponsor:   First Affiliated Hospital of Wenzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Conditions:   Hepatitis B;   Cirrhosis, Liver;   Chronic Liver Disease Interventions:   Biological: Heplisav-B Injectable Product, 2-dose regimen;   Biological: Heplisav-B Injectable Product, 3-dose regimen Sponsor:   Mercy Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Angiotensin 2 for AKI After OLT
Conditions:   Cirrhosis, Liver;   End Stage Liver DIsease;   Acute Kidney Injury;   Liver Transplant; Complications Interventions:   Drug: Angiotensin II;   Drug: Norepinephrine Sponsor:   University of California, Los Angeles Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Fecal Microbiota Transplantation in Cirrhosis
Condition:   Cirrhosis, Liver Intervention:   Other: Healthy fecal bacteria liquid Sponsor:   First Affiliated Hospital of Wenzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Angiotensin 2 for AKI After OLT
Conditions:   Cirrhosis, Liver;   End Stage Liver DIsease;   Acute Kidney Injury;   Liver Transplant; Complications Interventions:   Drug: Angiotensin II;   Drug: Norepinephrine Sponsor:   University of California, Los Angeles Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Fecal Microbiota Transplantation in Cirrhosis
Condition:   Cirrhosis, Liver Intervention:   Other: Healthy fecal bacteria liquid Sponsor:   First Affiliated Hospital of Wenzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Angiotensin 2 for AKI After OLT
Conditions:   Cirrhosis, Liver;   End Stage Liver DIsease;   Acute Kidney Injury;   Liver Transplant; Complications Interventions:   Drug: Angiotensin II;   Drug: Norepinephrine Sponsor:   University of California, Los Angeles Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Fecal Microbiota Transplantation in Cirrhosis
Condition:   Cirrhosis, Liver Intervention:   Other: Healthy fecal bacteria liquid Sponsor:   First Affiliated Hospital of Wenzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Angiotensin 2 for AKI After OLT
Conditions:   Cirrhosis, Liver;   End Stage Liver DIsease;   Acute Kidney Injury;   Liver Transplant; Complications Interventions:   Drug: Angiotensin II;   Drug: Norepinephrine Sponsor:   University of California, Los Angeles Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2020 Category: Research Source Type: clinical trials

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Conditions:   Hepatitis B;   Cirrhosis, Liver;   Chronic Liver Disease Interventions:   Biological: Heplisav-B Injectable Product, 2-dose regimen;   Biological: Heplisav-B Injectable Product, 3-dose regimen Sponsor:   Mercy Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2020 Category: Research Source Type: clinical trials